Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis
出版年份 2020 全文链接
标题
Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis
作者
关键词
-
出版物
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-02-11
DOI
10.1007/s40257-020-00507-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis
- (2019) Tamara Lund et al. Dermatologic Therapy
- Etanercept biosimilar SB 4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐center, observational, retrospective, real‐life study
- (2019) A. Giunta et al. BRITISH JOURNAL OF DERMATOLOGY
- AURIEL ‐PsO: A randomised, double‐blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
- (2019) J. Hercogová et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
- (2019) Christopher J. Edwards et al. CLINICAL RHEUMATOLOGY
- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
- (2018) Ross A. McKinnon et al. BIODRUGS
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- 814 - Phase Iii Randomized Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab in Patients with Active Crohn's Disease: 1-Year Maintenance and Switching Results
- (2018) Byong Duk Ye et al. GASTROENTEROLOGY
- Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis
- (2018) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry
- (2018) P. Gisondi et al. BRITISH JOURNAL OF DERMATOLOGY
- Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition
- (2018) Brian K. Chen et al. DRUGS
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
- (2017) S. Gerdes et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
- (2017) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
- (2016) Paolo Dapavo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
- (2016) Yoshiya Tanaka et al. Modern Rheumatology
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
- (2015) Jung-Yoon Choe et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
- (2015) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
- (2015) Tsutomu Takeuchi et al. Modern Rheumatology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started